Polycythemia on TRT: Managing Thick Blood & Thrombotic Risks

Polycythemia on TRT: When Blood Gets Too Thick Last Updated: JUNE 2024

Elevated hematocrit (HCT) above 50–52% on testosterone replacement therapy significantly correlates with increased blood viscosity and heightened risk of thrombotic events, including venous thromboembolism and stroke, as demonstrated in various studies involving hypogonadal men (Basaria et al., 2015, Annals of Internal Medicine). Understanding and managing this side effect is crucial for patient safety and long-term health outcomes on TRT. Effective management hinges on consistent monitoring, timely intervention, and a personalized approach to treatment.

Understanding Polycythemia and Erythrocytosis

Polycythemia, or erythrocytosis, refers to an increase in the absolute red blood cell (RBC) mass in the body. Clinically, this manifests as elevated hemoglobin and hematocrit levels. Hematocrit is the percentage of blood volume occupied by red blood cells. While polycythemia can be primary (e.g., Polycythemia Vera, a bone marrow disorder), the form observed in men on TRT is typically secondary erythrocytosis, meaning it is a reaction to an external stimulus—in this case, exogenous testosterone.

Normal hematocrit ranges for adult males typically fall between 40–50%. When on TRT, a hematocrit level consistently above 50% generally warrants attention, and levels exceeding 52% often require active management to mitigate health risks. A complete blood count (CBC) is the standard lab test used to monitor these levels.

Why TRT Can Lead to Elevated Hematocrit

Testosterone is a known stimulant of erythropoiesis, the process of red